{
    "id": 30576,
    "fullName": "EGFR L718V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR L718V lies within the protein kinase domain of the Egfr protein (UniProt.org). L718V results in increased kinase activity in combination with L858R and T790M (PMID: 29568384) and enhanced cell growth when combined with L858R in cultured cells, and is associated with resistance to Egfr inhibitors (PMID: 29571986), but has not been individually characterized and therefore, its effect on Egfr protein function is unknown.",
            "references": [
                {
                    "id": 17712,
                    "pubMedId": 29568384,
                    "title": "Structural insights into drug development strategy targeting EGFR T790M/C797S.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568384"
                },
                {
                    "id": 15765,
                    "pubMedId": 29571986,
                    "title": "Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29571986"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "L718V",
    "createDate": "07/23/2019",
    "updateDate": "01/30/2020",
    "referenceTranscriptCoordinates": {
        "id": 181322,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55174011C>G",
        "cDna": "c.2152C>G",
        "protein": "p.L718V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17775,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L718V and EGFR L858R were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29571986).",
            "molecularProfile": {
                "id": 32792,
                "profileName": "EGFR L718V EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15765,
                    "pubMedId": 29571986,
                    "title": "Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29571986"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17768,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L718V and EGFR L858R demonstrated resistance to treatment with Tagrisso (osimertinib) in culture (PMID: 29571986).",
            "molecularProfile": {
                "id": 32792,
                "profileName": "EGFR L718V EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15765,
                    "pubMedId": 29571986,
                    "title": "Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29571986"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17772,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L718V and EGFR L858R demonstrated resistance to treatment with Tarceva (erlotinib) in culture (PMID: 29571986).",
            "molecularProfile": {
                "id": 32792,
                "profileName": "EGFR L718V EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15765,
                    "pubMedId": 29571986,
                    "title": "Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29571986"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18031,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR L718V was identified as an acquired mutation at disease progression in a patient with lung adenocarcinoma harboring EGFR L858R who developed resistance to Tagrisso (osimertinib) (PMID: 31301016).",
            "molecularProfile": {
                "id": 32792,
                "profileName": "EGFR L718V EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15966,
                    "pubMedId": 31301016,
                    "title": "Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31301016"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17773,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L718V and EGFR L858R demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 29571986).",
            "molecularProfile": {
                "id": 32792,
                "profileName": "EGFR L718V EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15765,
                    "pubMedId": 29571986,
                    "title": "Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29571986"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17769,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L718V, EGFR L858R, and EGFR T790M demonstrated resistance to treatment with Tagrisso (osimertinib) in culture (PMID: 29571986).",
            "molecularProfile": {
                "id": 32793,
                "profileName": "EGFR L718V EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15765,
                    "pubMedId": 29571986,
                    "title": "Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29571986"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17829,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing an EGFR exon 19 deletion, EGFR L718V, and EGFR T790M demonstrated resistance to treatment with Tagrisso (osimertinib) in culture (PMID: 29571986).",
            "molecularProfile": {
                "id": 32794,
                "profileName": "EGFR exon 19 del EGFR L718V EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15765,
                    "pubMedId": 29571986,
                    "title": "Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29571986"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18045,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, tertiary EGFR mutations including C797S (n=3) and L718V (n=1) were identified as a potential acquired resistance mechanism in 13% (4/30) of patients with non-small cell lung cancer harboring EGFR T790M whose disease progressed while on Abivertinib (AC0010) treatment (PMID: 31027916; NCT02330367).",
            "molecularProfile": {
                "id": 32951,
                "profileName": "EGFR L718V EGFR T790M"
            },
            "therapy": {
                "id": 2909,
                "therapyName": "Abivertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15973,
                    "pubMedId": 31027916,
                    "title": "Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31027916"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20736,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, EGFR L718V with a coexisting EGFR T790M were identified in 1 of 100 patients with non-small cell lung cancer at treatment discontinuation of Tagrisso (osimertinib) (PMID: 31839416).",
            "molecularProfile": {
                "id": 32951,
                "profileName": "EGFR L718V EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18023,
                    "pubMedId": 31839416,
                    "title": "Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31839416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32791,
            "profileName": "EGFR L718V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32792,
            "profileName": "EGFR L718V EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32793,
            "profileName": "EGFR L718V EGFR T790M EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32794,
            "profileName": "EGFR exon 19 del EGFR L718V EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32951,
            "profileName": "EGFR L718V EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 181322,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55174011C>G",
            "cDna": "c.2152C>G",
            "protein": "p.L718V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}